clinical & translational science: individualizing cancer immunotherapy

Clinical & Translational Science:Individualizing Cancer ImmunotherapyScott A. Waldman, MD, PhD, FCPThomas Jefferson University

Clinical & Translational Science:

Individualizing Cancer Immunotherapy

Scott A. Waldman, MD, PhD, FCP

Director, Delaware Valley Institute for Clinical and Translational ScienceChair, Department of Pharmacology and Experimental Therapeutics

Director, GI Malignancies Program, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphia, Pennsylvania

Disclosures• I am the Chair of the Scientific Advisory Board of

Targeted Diagnostics & Therapeutics, Inc. (TDT; uncompensated)

• TDT provides research support to my laboratory• TDT licenses patents which are the subject of this

presentation• This technology has been sublicensed to

DiagnoCure, which does not provide support for this work

• I am entitled to a share of royalties collected by Thomas Jefferson University upon the sale of products resulting from patents on which I am an inventor

Delaware Health Sciences Alliance

Delaware Valley Institute for Clinical and Translational Science (DVICTS)

Translational Investigators

Colorectal Cancer and Women

Stage, Prognosis and Prediction

% of cases at presentation

Stage I Stage II Stage III Stage IV

% 5 yearsurvival

14

89 64 38 3

28 37 21

Stage

Recurrence (%)

20 40

Caucasian

African American

The One-Two Punch:Finding and Eradicating Occult Metastases

Guanylyl Cyclase C (GCC) as a Marker and Target in Colon Cancer

N T F Y C C E L C C N P A C A G C Y

The First Punch:Identifying Patients with Occult Metastases

Identifying Patients With Occult Metastases Using Molecular Detection

Low Risk (<5%)

High Risk (>80%)Hazard Ratio=65

The Second Punch:Eliminating Occult Metastases

Novel Vaccine Approaches to Colon Cancer: Cancer Mucosal Antigens

1

2

Tcell

APC

Cancer Mucosa Antigens

5 X

CRC Metastase

s

Effector T cells

43

20 30 400

20

40

60

80

100 ControlGCC

p<0.001

Days

Perc

ent S

urvi

val

Control GCC0

100

200

300

400

***

Immunization

Tum

or N

umbe

r

GCC Vaccine Protects Against Metastatic Colon Cancer in Mice

Individualizing Cancer Immunotherapy

20 30 400

20

40

60

80

100 ControlGCC

p<0.001

Days

Perc

ent S

urvi

val

AcknowledgementsThomas Jefferson University and Kimmel Cancer Center· Pharmacology

Stephanie Schulz Peng Li Janis Haaf Chris Bonaccorso Egeria Lin Ahmara Gibbon Michael

Valentino David Zuzga Adam Snook Alex Meija

• Medical Oncology Edith Mitchell

• Pathology Juan Palazzo

· Biostatistics Terry Hyslop

· Surgery Scott Goldstein Gerald Isenberg

Christiana Care Bruce Boman Nicholas Petrelli

Funding NIH PA

Department of Health

TDT, Inc.